MapLight
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
800 Chesapeake Dr, Redwood City, Califor...Phone Number
(617) 984-6300Website
www.maplightrx.comRevenue
-Stock Symbol
MPLTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About MapLight
MapLight Therapeutics is a Redwood City, California-based clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its proprietary discovery platform combines optogenetics, spatial transcriptomics, and circuit-mapping technologies to identify disease-linked neural circuits. The company’s pipeline targets schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, and Parkinson’s disease, with lead candidate ML-007C-MA in Phase 2 trials. MapLight completed its IPO and trades on the Nasdaq Global Market.Explore more
MapLight Org Chart
Get the full picture
Sign in to uncover key details.
RA
Vice President Clinical Pharmacology, Pharmac...
LC
Vice President & Head of Clinical Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MapLight your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
MapLight, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once MapLight has new funding data
Earning: See what the market has to say on MapLight recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at MapLight
Check out if MapLight is spiking on competitors!
Product Launch: Get notified when MapLight launches new products
Check if MapLight has recently received funding, and reach out quickly before it becomes old news!
Click to see if MapLight had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to MapLight
Compare insights from companies similar to MapLight, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
MapLight financials insights
Gather financial insights about MapLight, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series C
$225M
2025
Multiple Rounds
$819.6M
MapLight Tech Stack
A closer look at the technologies used by MapLight
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Christopher Kroeger received an option to purchase 93,955 shares and 23,145 RSUs on August 17, 2026.
Share Placement, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Research & Development, Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
MapLight News & Media
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trialMapLight Therapeutics Announces $150 Million Private Placement Financing
SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $150 million, before deductingMapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with an effect size of 0.37 (LS mean difference vs PBO -4.5, p=0.015)MapLight Therapeutics Announces Changes to Board of Directors
SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders, today announced the appointment of Martin Babler and Troy Cox to its Board of Directors following their election at the Company’s Annual Meeting of Stockholders on June 23, 2026. Mr. Babler and Mr. Cox succeed Robert Malenka, M.D., Ph.D., and
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MapLight
Sign Up For FreeTo access detailed company insights
MapLight Therapeutics is a Redwood City, California-based clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its proprietary discovery platform combines optogenetics, spatial transcriptomics, and circuit-mapping technologies to identify disease-linked neural circuits. The company’s pipeli... Read More
